Floatz logo

Pazopanib

Ovarian Neoplasm

The Christie NHS Foundation TrustSmall moleculePhase 2Dormant
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

79 Active assets in the Ovarian Neoplasm cohort.

Asset / SponsorPhaseRating
DOXORUBICIN
GlaxoSmithKline
Phase 4BBB
Carboplatin
Eli Lilly and Company
Phase 3BB
tlk286
Telik
Phase 3BB
Docetaxel
Merck Sharp & Dohme LLC
Phase 2BB
Niraparib
GlaxoSmithKline
Phase 4BB

View all 50 →

Same molecule, other indications

Pazopanib is also rated in:

renal cell carcinomaActive
BBB
Indicative · Phase 4
79 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative · Phase 2/3
69 / 100
View asset →
nonpapillary renal cell carcinomaActive
BB
Indicative · Phase 4
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →